D.A. Davidson & Co. Editas Medicine, Inc. Transaction History

D.A. Davidson & Co.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$26.55 - $40.57 $141,113 - $215,629	-5,315 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $3,141 - $5,835	-80 Reduced 1.48%	5,315 $218,000
Q2 2021 Aug 10, 2021	SELL	$31.29 - $56.64 $196,376 - $355,472	-6,276 Reduced 53.77%	5,395 $306,000
Q1 2021 May 07, 2021	SELL	$39.71 - $90.58 $84,224 - $192,120	-2,121 Reduced 15.38%	11,671 $490,000
Q4 2020 Feb 10, 2021	BUY	$27.07 - $84.35 $35,434 - $110,414	1,309 Added 10.49%	13,792 $967,000
Q3 2020 Nov 02, 2020	BUY	$28.06 - $37.16 $20,455 - $27,089	729 Added 6.2%	12,483 $350,000
Q2 2020 Aug 10, 2020	SELL	$18.5 - $34.34 $3,200 - $5,940	-173 Reduced 1.45%	11,754 $348,000
Q1 2020 May 05, 2020	BUY	$14.88 - $32.78 $34,700 - $76,442	2,332 Added 24.3%	11,927 $237,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $187,006 - $313,084	9,595 New	9,595 $284,000
Q2 2019 Aug 13, 2019	SELL	$20.48 - $27.76 $184,053 - $249,479	-8,987 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$19.43 - $26.41 $174,617 - $237,346	8,987 New	8,987 $220,000
Q4 2018 Jan 29, 2019	SELL	$18.19 - $31.79 $184,064 - $321,683	-10,119 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$27.65 - $38.39 $179,310 - $248,959	-6,485 Reduced 39.06%	10,119 $322,000
Q2 2018 Aug 02, 2018	BUY	$31.4 - $41.01 $15,762 - $20,587	502 Added 3.12%	16,604 $595,000
Q1 2018 May 04, 2018	BUY	$29.84 - $44.08 $221,323 - $326,941	7,417 Added 85.4%	16,102 $534,000
Q4 2017 Feb 08, 2018	BUY	$21.89 - $31.34 $190,114 - $272,187	8,685	8,685 $267,000

218

48.4M

436K

324K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $118M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.